Abstract
Maurice et al determine if Vitamin E, memantine, or both slow progression of mild to moderate Alzheimer's disease in patients taking an acetylchollnesterase inhibitor. Over the mean follow-up of 2.27 years, participants receiving alphatocopherol had slower decline than those receiving placebo as measured by the ADCS ADL. The change translates into a delay in clinical progression of 19% per year compared with placebo.
Author supplied keywords
- Activities of Daily Living
- Aged
- Aged, 80 & over
- Alzheimer Disease -- drug therapy
- Alzheimer Disease -- nursing
- Alzheimer Disease -- physiopathology
- Alzheimers disease
- Antioxidants
- Antioxidants -- adverse effects
- Antioxidants -- therapeutic use
- Caregivers
- Cholinesterase Inhibitors
- Cholinesterase Inhibitors -- therapeutic use
- Disease Progression
- Dopamine Agents
- Dopamine Agents -- adverse effects
- Dopamine Agents -- therapeutic use
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- Male
- Medical research
- Meetings And Congresses
- Memantine
- Memantine -- adverse effects
- Memantine -- therapeutic use
- Middle Aged
- Placebo effect
- Severity of Illness Index
- Treatment Outcome
- Vitamin E
- Vitamin E -- adverse effects
- Vitamin E -- therapeutic use
- article.aspx?articleid=1810379
Cite
CITATION STYLE
Dysken MD, M. W., Sano PhD, M., Asthana MD, S., Vertrees PharmD, BCPP, J. E., Pallaki MD, M., Llorente MD, M., … Guarino MPH, PhD, P. D. (2014). Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease: The TEAM-AD VA Cooperative Randomized Trial: The Journal of the American Medical Association The Journal of the American Medical Association. JAMA, 311(1), 33–44. Retrieved from https://ezproxy.help.edu.my/login?url=https://search.proquest.com/docview/1478020863?accountid=50218
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
